Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05245006Phase 1Active Not Recruiting

PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer

Role: collaborator

NCT05011188Phase 1Active Not Recruiting

FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer

Role: collaborator

NCT03575819Phase 1Completed

A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Role: lead

NCT03650491Phase 1Completed

A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Role: lead

All 4 trials loaded